| 发明名称 |
Combination of EGFR inhibitor and MEK inhibitor for use in the treatment of NRAS mutated cancer |
| 摘要 |
The invention relates to the methods for identifying resistance to cancer therapy, by identification of an E63K NRAS mutation, a G12V NRAS mutation or a gain of copy number of |
| 申请公布号 |
AU2015242407(A1) |
申请公布日期 |
2016.10.13 |
| 申请号 |
AU20150242407 |
申请日期 |
2015.04.02 |
| 申请人 |
AstraZeneca AB |
发明人 |
Cross, Darren Anthony Edward;Eberlein, Catherine Anne |
| 分类号 |
A61K31/4184;A61K31/506;A61P35/00 |
主分类号 |
A61K31/4184 |
| 代理机构 |
|
代理人 |
|
| 主权项 |
|
| 地址 |
|
